UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 250

Sortiert nach

Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen zwischen wissenschaftlichem Fortschritt und medizinischer Versorgungsrealität: Eine Standortbestimmung

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2012-03, Vol.55 (3), p.343-350

2012

Volltextzugriff (PDF)

Omalizumab inhibits allergen challenge-induced nasal response

The European respiratory journal, 2004-03, Vol.23 (3), p.414-418

2004

Volltextzugriff (PDF)

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

The European respiratory journal, 2002-11, Vol.20 (5), p.1088-1094

2002

Volltextzugriff (PDF)

Correlation between immune and neuronal parameters and stress perception in allergic asthmatics

Clinical and experimental allergy, 2008-02, Vol.38 (2), p.283-290

2008

Volltextzugriff (PDF)

The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics

Clinical and experimental allergy, 2003-05, Vol.33 (5), p.649-654

2003

Volltextzugriff (PDF)

The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics

Clinical and experimental allergy, 2001-12, Vol.31 (12), p.1906-1912

2001

Volltextzugriff (PDF)

Selective induction of nerve growth factor and brain-derived neurotrophic factor by LPS and allergen in dendritic cells

Clinical and experimental allergy, 2008-03, Vol.38 (3), p.473-479

2008

Volltextzugriff (PDF)

Differential activation of dendritic cells by nerve growth factor and brain-derived neurotrophic factor

Clinical and experimental allergy, 2007-11, Vol.37 (11), p.1701-1708

2007

Volltextzugriff (PDF)

Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils

Clinical and experimental allergy, 2002-09, Vol.32 (9), p.1348-1354

2002

Volltextzugriff (PDF)

Omalizumab decreased IgE‐release and induced changes in cellular immunity in patients with allergic asthma

Allergy (Copenhagen), 2006-09, Vol.61 (9), p.1141-1144

2006

Volltextzugriff (PDF)

Molecular allergy diagnosis using pollen marker allergens and pollen panallergens: Five patterns seen in multiple test reactions to pollen extracts

Allergologie select, 2021-01, Vol.5 (1), p.180-186

2021

Volltextzugriff (PDF)

Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis

Journal of investigational allergology & clinical immunology, 2009, Vol.19 (6), p.459-464

2009

Volltextzugriff (PDF)

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma

Journal of Allergy and Clinical Immunology, 2006-06, Vol.117 (6), p.1493-1499

2006

Volltextzugriff (PDF)

Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab

International archives of allergy and immunology, 2003-05, Vol.131 (1), p.46-52

2003

Volltextzugriff (PDF)

Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis

Inflammation research, 2000-10, Vol.49 (10), p.520-523

2000

Volltextzugriff (PDF)

Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic Asthmatics

International archives of allergy and immunology, 2008-04, Vol.146 (1), p.66-70

2008

Volltextzugriff (PDF)

From the Authors

The European respiratory journal, 2004-08, Vol.24 (2), p.330-331

2004

Volltextzugriff (PDF)

Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3

Regulatory peptides, 2005-01, Vol.124 (1), p.19-25

2005

Volltextzugriff (PDF)

Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2012-03, Vol.55 (3), p.343-350

2012

Volltextzugriff (PDF)

Regulation of NGF and BDNF by dexamethasone and theophylline in human peripheral eosinophils in allergics and non-allergics

Regulatory peptides, 2005-12, Vol.132 (1), p.74-79

2005

Volltextzugriff (PDF)

Short communication: Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma

Allergy (Copenhagen), 2006-09, Vol.61 (9), p.1141

2006

Volltextzugriff (PDF)

Omalizumab (rhuMAb-E25) hemmt die IgE-Freisetzung stimulierter PBMC bei allergischen Asthmatikern in vitro

Pneumologie, 2005, Vol.59 (S 1)

2005

Volltextzugriff (PDF)

The role of omalizumab or rhuMAB-E25 in the treatment of allergic rhinitis

The European respiratory journal, 2004-08, Vol.24 (2), p.330; author reply 330-330

Lee, D K C

2004

Volltextzugriff (PDF)

Omalizumab (rhuMAb-E25) induziert Apoptose in eosinophilen Granulozyten bei allergischen Atshmatikern

Pneumologie, 2005

2005

Volltextzugriff (PDF)

Ozone-Induced Release of Neuropeptides from Human Nasal Mucosa Cells

International archives of allergy and immunology, 2002-10, Vol.129 (2), p.145-151

2002

Volltextzugriff (PDF)

1 – 25 von 250

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(221)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Humans
(66)
Life Sciences & Biomedicine
(63)
Physics
(53)
Physical Sciences
(51)
Male
(40)
Female
(39)
Physics, Condensed Matter
(36)
Biological And Medical Sciences
(32)
Exact Sciences And Technology
(32)
Materials Science
(30)
Middle Aged
(29)
Technology
(28)
Adult
(27)
Applied Sciences
(22)
Medical Sciences
(22)
Materials Science, Multidisciplinary
(21)
Metals. Metallurgy
(21)
Physics, Applied
(20)
Chemistry
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen zwischen wissenschaftlichem Fortschritt und medizinischer Versorgungsrealität: Eine Standortbestimmung

Omalizumab inhibits allergen challenge-induced nasal response

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

Correlation between immune and neuronal parameters and stress perception in allergic asthmatics

The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics

The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics

Selective induction of nerve growth factor and brain-derived neurotrophic factor by LPS and allergen in dendritic cells

Differential activation of dendritic cells by nerve growth factor and brain-derived neurotrophic factor

Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils

Omalizumab decreased IgE‐release and induced changes in cellular immunity in patients with allergic asthma

Molecular allergy diagnosis using pollen marker allergens and pollen panallergens: Five patterns seen in multiple test reactions to pollen extracts

Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma

Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab

Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis

Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic Asthmatics

From the Authors

Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3

Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation

Regulation of NGF and BDNF by dexamethasone and theophylline in human peripheral eosinophils in allergics and non-allergics

Short communication: Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma

Omalizumab (rhuMAb-E25) hemmt die IgE-Freisetzung stimulierter PBMC bei allergischen Asthmatikern in vitro

The role of omalizumab or rhuMAB-E25 in the treatment of allergic rhinitis

Omalizumab (rhuMAb-E25) induziert Apoptose in eosinophilen Granulozyten bei allergischen Atshmatikern

Ozone-Induced Release of Neuropeptides from Human Nasal Mucosa Cells

Suchergebnisse filtern